Two new consultations have opened on the GMMMG website. To take part, visit the consultations page.
CRG actions February 2025
On behalf of the GMMMG Clinical Reference Group, we now seek comments on the actions proposed at the February 2025 CRG meeting. Actions in this consultation include:
- Vamorolone for treating Duchenne muscular dystrophy – RED
- Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease – RED
All links to NICE clinical guidelines and MHRA drug safety updates will be added to formulary as appropriate.
To take part, visit consultation: CRG actions February 2025.
FAQs on implementation of topiramate safety measures
This document compiles FAQs regarding the new safety measures for topiramate, introduced by the MHRA in June 2024. The responses have been reviewed by members of the Valproate subgroup and IPMO Medicine Safety subgroup, incorporating cross-sector representation across GM, as well as specialist input.
To take part, visit consultation: FAQs on implementation of topiramate safety measures.